Summary statistics - qualitative results

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test Sample	Group		N	Result	N_{rel}
Set 1					
(560) ANA screening (cell nucleus) - prove					
A1	All results		7	Negative	9,1 %
			2	Inconclusive result (borderline)	2,6 %
		>>>	68	Positive	88 %
	Total per sample: n = 77	Success: 88 %			
B1	All results	>>>	77	Negative	100 %
	Total per sample: n = 77	Success: 100 %			
Total success: 88 %					
(572) ANA screening (cell nucleus) - semi-quantity					
A1	All results	±	6	titre 40	9,1 %
		±	10	titre 80	15 %
		±	26	titre 160	39 %
		±	15	titre 320	23 %
		±	6	titre 640	9,1 %
		±	2	titre 1280	3,0 %
		±	1	titre 2560	1,5 %
	Total per sample: n = 66	Success (only evaluated results): evaluation			
B1	All results	±	45	titre 0 (not measurable)	68 %
		±	14	titre 40	21 %
		±	6	titre 80	9,1 %
		±	1	titre 2560	1,5 %
	Total per sample: n = 66	Success (only evaluated results): evaluation			
(561) ANA - type of fluorescence - nucleus					
A1	All results	±	1	No fluorescence	1,5 %
		±	20	Coarse speckled	29 %
		±	2	Coarse speckled; Fine speckled	2,9 %
		±	2	Coarse speckled; Nuclear matrix	2,9 %
		±	28	Fine speckled	41 %
		±	12	Nuclear matrix	18 %
		±	2	Nuclear matrix; Coarse speckled	2,9 %
		±	1	Unknown type of fluorescence	1,5 %
	Total per sample: n = 68	Success (only evaluated results): evaluation			
B1	All results	>>>	68	No fluorescence	100 %
	Total per sample: n = 68	Success: 100 %			
(563) ANA screening (cytoplasma) - prove					
A1	All results	>>>	64	Negative	94 %
			1	Inconclusive result (borderline)	1,5 %
			3	Positive	4,4 %
	Total per sample: n = 68	Success: 94 %			
B1	All results	>>>	67	Negative	99 %
			1	Positive	1,5 %
	Total per sample: n = 68	Success: 99 %			
Total success: 93 %					
(573) ANA screening (cytoplasma) - semi-quantity					
A1	All results	±	39	titre 0 (not measurable)	62 %
		±	13	titre 40	21 %
		±	8	titre 80	13 %
		±	1	titre 160	1,6 %
		±	1	titre 320	1,6 %
		±	1	titre 2560	1,6 %
	Total per sample: n = 63	Success (only evaluated results): evaluation			
B1	All results	±	41	titre 0 (not measurable)	65 %
		±	15	titre 40	24 %
		±	6	titre 80	9,5 %
		±	1	titre 2560	1,6 %
	Total per sample: n = 63	Success (only evaluated results): evaluation			
(564) ANA - type of fluorescence - cytoplasma					
A1	All results	>>>	61	No fluorescence	94 %
			1	Fine speckled cytoplasmic pattern	1,5 %
			3	Diffusion cytoplasmic picture	4,6 %
	Total per sample: n = 65	Success: 94 %			
B1	All results	>>>	64	No fluorescence	98 %
			1	Diffusion cytoplasmic picture	1,5 %
	Total per sample: n = 65	Success: 98 %			

Test Sample	Group		N	Result	N_{rel}
Total success: 92 %					

Set 2

(565) ANCA imunofluorescence - prove

A2	All results	>>>	63	Positive	100 %
	Total per sample: n = 63	Success: 100 %			
B2	All results	>>>	63	Negative	100 %
	Total per sample: n = 63	Success: 100 %			
Total success: 100 %					

(574) ANCA IF (ethanol) - semi-quantity

A2	All results	±	1	Not specified	1,9 %
		±	4	titre 20	7,4 %
		±	5	titre 40	9,3 %
		±	9	titre 80	17 %
		±	12	titre 160	22 %
		±	13	titre 320	24 %
		±	5	titre 640	9,3 %
		±	3	titre 1280	5,6 %
		±	2	titre 2560	3,7 %
	Total per sample: n = 54	Success (only evaluated results): evaluation			
B2	All results	±	35	titre 0 (not measurable)	65 %
		±	19	titre 20	35 %
	Total per sample: n = 54	Success (only evaluated results): evaluation			

(578) ANCA IF (formalin) - semi-quantity

A2	All results	±	1	Not specified	1,9 %
		±	4	titre 20	7,5 %
		±	8	titre 40	15 %
		±	8	titre 80	15 %
		±	14	titre 160	26 %
		±	12	titre 320	23 %
		±	2	titre 640	3,8 %
		±	2	titre 1280	3,8 %
		±	2	titre 2560	3,8 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			
B2	All results	±	34	titre 0 (not measurable)	64 %
		±	19	titre 20	36 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			

(566) ANCA - type of fluorescence

A2	All results	>>>	56	Perinuclear fluorescence	90 %
		>>>	6	Perinuclear fluorescence; ANA	9,7 %
	Total per sample: n = 62	Success: 100 %			
B2	All results		1	Not specified	1,6 %
		>>>	61	No fluorescence	98 %
	Total per sample: n = 62	Success: 98 %			
Total success: 98 %					

(569) anti-myeloperoxidase

A2	All results		1	Negative	1,4 %
			1	Inconclusive result (borderline)	1,4 %
		>>>	70	Positive	97 %
	Total per sample: n = 72	Success: 97 %			
B2	All results	>>>	71	Negative	99 %
			1	Positive	1,4 %
	Total per sample: n = 72	Success: 99 %			
Total success: 97 %					

(570) anti-proteinase III

A2	All results	>>>	72	Negative	100 %
	Total per sample: n = 72	Success: 100 %			
B2	All results	>>>	72	Negative	100 %
	Total per sample: n = 72	Success: 100 %			
Total success: 100 %					

Set 3

(580) Anti-ENA/SS-A/Ro-60

A3	All results		1	Negative	1,4 %
		>>>	73	Positive	99 %
	Total per sample: n = 74	Success: 99 %			
B3	All results	>>>	64	Negative	86 %
			5	Inconclusive result (borderline)	6,8 %
			5	Positive	6,8 %
	Total per sample: n = 74	Success: 86 %			

Test Sample	Group		N	Result	N_{rel}
Total success: 85 %					
(581) Anti-ENA/SS-B/La					
A3	All results	>>>	68	Negative	92 %
			4	Inconclusive result (borderline)	5,4 %
			2	Positive	2,7 %
	Total per sample: n = 74	Success: 92 %			
B3	All results	>>>	74	Negative	100 %
	Total per sample: n = 74	Success: 100 %			
Total success: 92 %					
(582) Anti-ENA/Scl-70					
A3	All results	>>>	74	Negative	100 %
	Total per sample: n = 74	Success: 100 %			
B3	All results	>>>	74	Negative	100 %
	Total per sample: n = 74	Success: 100 %			
Total success: 100 %					
(583) Anti-ENA/RNP					
A3	All results	>>>	68	Negative	92 %
			6	Inconclusive result (borderline)	8,1 %
	Total per sample: n = 74	Success: 92 %			
B3	All results	>>>	70	Negative	95 %
			2	Inconclusive result (borderline)	2,7 %
			2	Positive	2,7 %
	Total per sample: n = 74	Success: 95 %			
Total success: 86 %					
(584) Anti-ENA/Jo-1					
A3	All results	>>>	74	Negative	100 %
	Total per sample: n = 74	Success: 100 %			
B3	All results	>>>	74	Negative	100 %
	Total per sample: n = 74	Success: 100 %			
Total success: 100 %					
(585) Anti-centromere antibodies					
A3	All results	>>>	68	Negative	100 %
	Total per sample: n = 68	Success: 100 %			
B3	All results	>>>	68	Negative	100 %
	Total per sample: n = 68	Success: 100 %			
Total success: 100 %					
Set 4					
(588) Anti-ds-DNA immunofluores. - prove					
A4	All results	>>>	56	Positive	100 %
	Total per sample: n = 56	Success: 100 %			
B4	All results	>>>	56	Negative	100 %
	Total per sample: n = 56	Success: 100 %			
Total success: 100 %					
(577) Anti-ds-DNA immunofluor. - semi-quantity					
A4	All results	±	1	titre 10	1,9 %
		±	10	titre 80	19 %
		±	10	titre 160	19 %
		±	17	titre 320	32 %
		±	13	titre 640	25 %
		±	2	titre 1280	3,8 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			
B4	All results	±	36	titre 0 (not measurable)	68 %
		±	17	titre 10	32 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			
(589) Anti-ds-DNA other methods					
A4	All results		1	Negative	1,8 %
			1	Inconclusive result (borderline)	1,8 %
		>>>	55	Positive	96 %
	Total per sample: n = 57	Success: 96 %			
B4	All results	>>>	57	Negative	100 %
	Total per sample: n = 57	Success: 100 %			
Total success: 96 %					

Summary statistics - qualitative results

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Test

Sample	Group	N	Result	N_{rel}
Set 5				
(591) Anti-nucleosomes IgG				
A5	All results	2	Inconclusive result (borderline)	3,8 %
		>>> 51	Positive	96 %
	Total per sample: n = 53 - Success: 96 % -			
B5	All results	1	Not specified	1,9 %
		>>> 52	Negative	98 %
	Total per sample: n = 53 - Success: 98 % -			

Total success: 94 %